AzTrials
AzTrials

Breast Cancer (Early Breast Cancer)NCT07071402

A Study on the Treatment of Early Small Breast Cancer With Ultrasound-guided Vacuum-assisted Excision Combined With Surgery

A study testing Ultrasound-guided vacuum-assisted excision combined with surgical treatment in people with Breast Cancer (Early Breast Cancer), run by Xijing Hospital at 1 site in China.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record

Search all trials

Trial summary

The aim of this clinical trial is to assess the feasibility and safety of ultrasound-guided vacuum-assisted excision (VAE) in the treatment of early breast cancer with Tis (carcinoma in situ) or T1 (maximum tumor diameter ≤2cm) and negative axillary lymph nodes on imaging. Read more about this study

Who is it for?
Ages 18 to 70 years, women only
Conditions the study is for
Breast Cancer (Early Breast Cancer)
What is being tested?
Ultrasound-guided vacuum-assisted excision combined with surgical treatment
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
120 participants
Where
1 siteChina
Study dates
18 Jul 2025to 1 Jun 2029
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Subjects must meet all of the following inclusion criteria to be enrolled in this trial:
  • Age: 18 - 70 years old;
  • Female patients;
  • Patients diagnosed with suspected breast cancer through imaging (such as breast ultrasound, mammography, etc.) with BI - RADS Category 4C and Category 5;
  • Clinical stage T1: Mass ≤2cm;
  • No previous treatment related to breast cancer;
  • Be willing to undergo ultrasound - guided vacuum - assisted resection, biopsy and surgical treatment; 7) The subjects voluntarily join this study and sign the informed consent form.

Who cannot join

  • Those with any of the following circumstances will not be selected as subjects:
  • Imaging suggests that the lesion is greater than 2cm;
  • Suspected positive axillary lymph nodes in imaging (Bedi 4, Bedi 5, Bedi 6);
  • The tumor invades the nipples, areolas and subcutaneous tissues;
  • Breast cancer during pregnancy;
  • Abnormal functions of vital organs such as the heart, lungs, liver and kidneys, and poorly controlled diabetes, etc., cannot tolerate surgery;
  • Any other circumstances in which the researcher deems the patient unsuitable to participate in this study.

Trial locations and contacts

1 site in 1 country.

China1 site
  • Xijing hospital

    Xi'an, Shaanxi, 710032

Other trials in China

About this study

Official title: A Single-center, Single-arm, Open Study on the Treatment of Early Small Breast Cancer With Ultrasound-guided Vacuum-assisted Excision Combined With Surgery

The aim of this clinical trial is to assess the feasibility and safety of ultrasound-guided vacuum-assisted excision (VAE) in the treatment of early breast cancer with Tis (carcinoma in situ) or T1 (maximum tumor diameter ≤2cm) and negative axillary lymph nodes on imaging. The main question it aims to answer is:

  • After VAE, when undergoing routine breast cancer surgery again, what is the complete resection rate of the lesion in the surgically removed tissue (pathologically confirmed), that is, the false negative rate of VAE?
  • Which type of breast cancer lesion has the highest complete resection rate?
  • Is it clear whether VAE can be applied in the treatment of early breast cancer with Tis or T1 and negative axillary lymph nodes on imaging?
  • Do patients with benign breast nodules who undergo VAE or are recommended for Vacuum-assisted breast biopsy (VABB) due to limited puncture and are diagnosed with breast cancer need to undergo surgery again?
  • The incidence of complications of VAE.
Read more

Participants will:

  • Single early breast cancer subjects with Tis or T1 and negative axillary lymph nodes on imaging, after being fully informed and signing the informed consent form, enter the trial period after screening and being qualified.
  • After the subjects are confirmed to be enrolled, VAE biopsy resection is performed first.
  • Patients clearly diagnosed with breast cancer receive traditional radical mastectomy for breast cancer: Breast-conserving surgery or total mastectomy, sentinel lymph node biopsy or dissection in the axilla, assessment of whether the lesion has been completely removed based on postoperative pathology, and follow-up is conducted.
Read the detailed description

This is a single-arm and single-center clinical study. The specific implementation steps of the study are as follows:

  1. Patient recruitment and screening Recruit eligible patients through channels such as the breast surgery outpatient department of the hospital. Conduct a preliminary assessment of potential patients, including medical history inquiry, physical examination, and imaging examinations (breast ultrasound, mammography, etc.), to determine whether they meet the inclusion criteria. Adopt the Common Decision Questionnaire (SDM-Q-9). Evaluate the patients and select those with better compliance and a standardized total score of the scale ≥80. Introduce in detail the research purpose, methods, risks and benefits, etc. to the patients who meet the inclusion criteria and the assessment, and obtain the written informed consent forms of the patients.
  2. VAE surgery Ultrasound-guided vacuum-assisted resection: Place the patient in an appropriate position, and use a routine disinfection towel. Locate the tumor location by ultrasound. After local anesthesia, percutaneously puncture a vacuum-assisted rotary cutting needle beneath the tumor. Under ultrasound guidance, gradually remove the tumor tissue until the ultrasound shows that the tumor is completely resected. Send the resected tissue for pathological examination.
  3. Follow-up surgery After the patient is confirmed to have breast cancer through VAE resection biopsy, according to the specific condition of the patient, perform radical mastectomy for breast cancer in the hospital. The surgical methods can be breast-conserving surgery or mastectomy. At the same time, perform sentinel lymph node biopsy, and send the resected tissue for pathological examination. The surgical process follows the procedures for breast cancer surgical treatment norms.
  4. Postoperative assessment Pathological assessment: Conduct a detailed pathological examination on the specimens removed by vacuum-assisted resection and subsequent surgical resection, including tumor size, histological grade, molecular typing, resection margin conditions, and tumor residue conditions, etc. Complication assessment: Observe whether complications such as bleeding, infection, breast tissue injury, poor incision healing, and lymphatic leakage occur in patients during vacuum-assisted resection and subsequent surgeries. Record the occurrence time, severity, and treatment measures of complications. Evaluation of surgical satisfaction, treatment satisfaction and quality of life satisfaction: After the operation, give chemotherapy, targeted therapy or endocrine therapy according to the diagnosis and treatment routine. The treatment plan follows the recommendations of guidelines such as NCCN. If local radiotherapy is required, carry it out according to the clinical routine. At 1 week, 1 month, 3 months and 6 months after the operation at time points such as months, evaluate the surgical satisfaction, treatment satisfaction and quality of life satisfaction of the patients.
  5. Establish a database for follow-up Utilize the existing breast cancer database of the department to establish individual information data for patients, recording their general information, diagnosis and treatment processes, and other data.
Being tested
Ultrasound-guided vacuum-assisted excision combined with surgical treatment
Keywords
vacuum-assisted excision
Medical subject headings
Breast Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ultrasound-guided vacuum-assisted excision combined with surgical treatmentProcedure or surgery

    Patients undergoing VAE surgery (EnCor® vacuum-assisted minimally invasive rotary system)are placed in an appropriate position, undergo routine disinfection and blanching, and the tumor location is located by ultrasound. After local anesthesia, a vacuum-assisted rotary cutting needle is percutaneous punctured beneath the tumor. Under ultrasound guidance, the tumor tissue is gradually resected until the ultrasound shows complete tumor resection. The resected tissue is sent for pathological examination. After the patient is confirmed to have breast cancer through VAE resection biopsy, depending on the patient's specific condition, they are hospitalized for radical mastectomy. The surgical methods can be breast-conserving surgery or mastectomy. At the same time, sentinel lymph node biopsy is performed, and the resected tissue is sent for pathological examination. The surgical process follows the surgical treatment norms for breast cancer.

Study groups in NCT07071402
Study groupRoleWhat they receive
Ultrasound-guided VAE combined with surgery for the treatment of early small breast cancerExperimentalSingle early breast cancer subjects with Tis (carcinoma in situ) or T1 (maximum tumor diameter ≤2cm) and negative axillary lymph nodes on imaging, after being fully informed and signing the informed consent form, and passing the screening, enter the trial period. After the subjects are confirmed to be enrolled, VAE is performed first. Patients with a clear diagnosis of breast cancer receive traditional radical mastectomy for breast cancer: Breast-conserving surgery or total mastectomy, and sentinel lymph node biopsy or dissection in the axilla. The complete resection of the lesion is evaluated based on the postoperative pathology, and follow-up is conducted.
Receives: Procedure: Ultrasound-guided vacuum-assisted excision combined with surgical treatment

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The complete resection rate of the lesion in the surgically resected tissue after vacuum-assisted excision under ultrasound guidance

    The proportion of patients whose tumor tissues are completely resected by VAE confirmed through postoperative pathological examination, that is, the false negative rate of VAE

    Measured: Two weeks after the operation

Secondary outcomes (3)
  1. Incidence of surgery-related complications

    The occurrence of complications such as bleeding, infection, breast tissue injury, poor incision healing and lymphatic leakage during VAE and subsequent surgical procedures

    Measured: During the operation, 3 days after the operation, 2 weeks after the operation, 1 month after the operation

  2. The local recurrence rate of the breast and axilla

    The patients are followed up to evaluate whether there is recurrence of breast and axillary lesions

    Measured: Two years after the operation

  3. Patient satisfaction

    The BREAST Q2 questionnaire is used for the investigation

    Measured: Three months after the operation

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Jul 2025
  2. Study start18 Jul 2025
  3. Primary completion1 Jun 2028 (estimated)
  4. Study completion1 Jun 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07071402
Sponsor's protocol ID
KY-20252227-F-1
Status last verified
Oct 2026
First submitted
29 Jun 2025
Last updated
13 Oct 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
Undecided

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in